- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03703050
Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL)
Phase II Trial of Nivolumab for Pediatric and Adult Relapsing/Refractory Anaplastic Large Cell Lymphoma, for Evaluation of Response in Patients With Progressive Disease Cohort 1 or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse Cohort 2
Study Overview
Status
Intervention / Treatment
Detailed Description
Prospective, non-randomized, single arm phase II trial with 2 cohorts of ALK+ ALCL treated with nivolumab
Cohort 1:
Population: relapsed/refractory ALK+ ALCL with progressive disease after treatment (including chemotherapy and ALK inhibitor and/or brentuximab vedotin).
Primary endpoint: ORR = best objective response rate (CR+PR) within the first 24 weeks, assessed according to adapted Lugano 2014 response criteria for Lymphoma.
Design: A one-stage phase II trial with unacceptable ORR = 40% and promising ORR = 70%. 12 eligible and evaluable patients are required.
Cohort 2 Population: patients with a relapsed/refractory ALCL, having achieved CR with a treatment including ALK-inhibitor or Brentuximab vedotin of at least 2 months and for whom HSCT is considered for their consolidation therapy. In this case, nivolumab for 24 months would be considered as consolidative immunotherapy instead as HSCT.
Primary endpoint: progression-free survival (PFS) A PFS rate ≤ 50% will be considered as unacceptable. Design: A four-stage phase II trial with unacceptable PFS rate = 50% and promising PFS rate = 75%. A maximum of twenty-six patients will be included: 4 at the 1st and 2nd stages, 8 at the 3rd stage and 10 at the 4th stage.
No more than one third of the included patients must have received more than 12 months of ALK inhibitor or brentuximab. Thus, the inclusion of these patients will be closed after 8 patients.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Veronique Minard, Pr
- Phone Number: +33 (0)1 42 11 41 70
- Email: veronique.minard@gustaveroussy.fr
Study Contact Backup
- Name: Anne AUPERIN, MD
- Phone Number: +33 (0)1 42 11 54 99
- Email: anne.auperin@gustaveroussy.fr
Study Locations
-
-
-
Copenhagen, Denmark
- Recruiting
- Rigshospitalet
-
Contact:
- Karsten Nysom, MD
- Email: Karsten.Nysom@regionh.dk
-
-
-
-
-
Bordeaux, France, 33076
- Recruiting
- CHU Bordeaux Hôpital Pellegrin
-
Contact:
- stephane DUCASSOU, MD
- Email: stephane.ducassou@chu-bordeaux.fr
-
Bordeaux, France
- Recruiting
- GROS
-
Contact:
- GROS François, MD
-
Créteil, France
- Recruiting
- SIBON
-
Contact:
- SIBON David, MD
- Phone Number: 0145178245
- Email: david.sibon@aphp.fr
-
Lille, France
- Recruiting
- BARBATI
-
Contact:
- BARBATI Melissa, MD
-
Contact:
- Phone Number: 0320444105
- Email: melissa.barbati@chu-lille.fr
-
Lyon, France, 69008
- Recruiting
- Centre Léon Bérard Lyon
-
Contact:
- Anne -Sophie Michalet, MD
- Email: sophie.michallet@ihop.fr
-
Paris, France, 75010
- Withdrawn
- Hôpital Saint Louis
-
Paris, France, 75012
- Recruiting
- Landman-Parker
-
Contact:
- LANDMAN-PARKER Judith, MD
- Phone Number: 0171738857
- Email: judith.landman-parker@aphp.fr
-
Toulouse, France, 31059
- Recruiting
- CHU Toulouse Hopital des Enfants
-
Contact:
- Marlène Pasquet, MD
- Email: marlène.pasquet@chu-toulouse.fr
-
Toulouse, France, 31059
- Recruiting
- IUC Toulouse
-
Contact:
- Lucie Oberic, MD
- Phone Number: +33 (0)5 31 15 63 53
- Email: oberic.lucie@iuct-oncopole.fr
-
Vandœuvre-lès-Nancy, France, 54500
- Recruiting
- Chu de Nancy
-
Contact:
- PHULPIN Aurélie, MD
- Email: a.phulpin@chru-nancy.fr
-
-
Val De Marne
-
Villejuif, Val De Marne, France, 94805
- Recruiting
- Gustave Roussy
-
Contact:
- Véronique Minard, MD
- Phone Number: +33 (0)1 42 11 41 70
- Email: veronique.minard@gustaveroussy.fr
-
-
-
-
-
Utrecht, Netherlands
- Not yet recruiting
- Princess Maxima Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
All criteria from I-1 to I-10 are required for all patients, in addition of the cohort-specific criteria
I-1. Histologically confirmed evidence of relapsed/refractory ALK+ ALCL. If biopsy could not be performed, relapsed/refractory status should be confirmed by molecular analysis whenever possible (increase of MRD quantitative PCR at 2 consecutive measures qualifying for a significant increase according to the same reference laboratory, with clinical signs and symptoms suggestive of progressing disease). In this case, relapsed/refractory status must be reviewed and confirmed by the international coordinating investigator.
I-2. Age at inclusion > 6 months I-3. No washout needed, but patients must have recovered from acute toxic effects of all prior therapy before enrollment into the study. A short course of steroids is allowed at the beginning of Nivolumab if it is clinical indicated
I-4. Adequate organ function:
- Peripheral absolute neutrophil count (ANC) ≥750/μL in patients without bone marrow involvement and ≥500/μL in patients with bone marrow involvement (unsupported)
- Platelet count ≥75,000/μL in patients without bone marrow involvement and 50 000 in patients with bone marrow involvement (unsupported)
- Hemoglobin ≥8.0 g/dL (transfusion is allowed)
- Serum creatinine ≤1.5 x upper limit of normal (ULN) for age
- Total bilirubin ≤1.5 x ULN in patients without liver involvement and < 2.5 ULN in patients with liver involvement
- Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) ≤3 x ULN in patients without liver involvement and < 5 ULN in patients with liver involvement
- Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase/SGOT ≤3 x ULN in patients without liver involvement and < 5 ULN in patients with liver involvement I-5. Performance status: Karnofsky performance status (for patients >12 years of age) or Lansky Play score (for patients ≤12 years of age) ≥ 40%.
I-6. Able to comply with the scheduled disease management (treatment and follow-up), and with the management of toxicity I-7. Females of childbearing potential must have a negative serum β-HCG pregnancy test within 24 hours prior to initiation of treatment. Sexually active women of childbearing potential must agree to use acceptable and appropriate contraception during the study and for at least 5 months after the last study treatment administration. Sexually active males patients must agree to use condom during the study and for at least 7 months after the last study treatment administration. I-8. Written informed consent from parents/legal representative, patient, and age-appropriate assent before any study-specific screening procedures are conducted according to local, regional or national guidelines.
I-9. Patient affiliated to a social security regimen or beneficiary of the same according to local requirements.
I-10. Patients will prior allogeneic HSCT may be included if clinically indicated (see non-inclusion criteria regarding prior allogeneic HSCT). In this case, study inclusion must be confirmed by the international coordinating investigator.
Cohort 1:
For being enrolled in Cohort 1, all criteria from C1.I-1 to C1.I-2 are required, in addition of I-1 to I-10 criteria C1.I-1. Measurable progressive disease with at least one lesion measuring more than 1.5 cm and/or evaluable disease on PET-CT C1.I-2. Previous treatment including chemotherapy and ALK inhibitor or brentuximab vedotin, if available.
Cohort 2:
For being enrolled in Cohort 2, all criteria from C2.I-1 to C2.I-2 are required, in addition of I-1 to I-10 criteria C2.I-1. Complete response (disappearance of all disease except for possible detection of MRD in blood and/or bone marrow) with an on-going treatment of at least 2 months with ALK inhibitor or brentuximab vedotin, if available combined or not with chemotherapy C2.I-2. High-risk relapsed/refractory ALK+ ALCL for whom an hematopoietic stem cell transplantation is considered after CR
Exclusion Criteria:
E-1. Patients with prior allogeneic HSCT less than 3 months before study inclusion E-2. Patients with prior allogeneic HSCT and any active graft versus host disease (GVHD) and/or any prior grade 3 or 4 GVHD according to International Bone Marrow Transplant Registry (ITBMR) E-3. Previous organ transplantation E-4. Significant hemophagocytosis in bone marrow, spleen, lymph nodes, or liver must be discussed with the Coordinating Sponsor before inclusion E-5. Presence of any ≥ CTCAE grade 2 treatment-related toxicity with the exception of alopecia, fatigue and peripheral neuropathy.
E-6. History or evidence of severe uncontrolled illness that contra-indicates use of an investigational drug, or places the patient at unacceptable risk from treatment complications E-7. History or evidence of severe acute or chronic infection unless fully healed at least four weeks prior to screening E-8. Known human immunodeficiency virus (HIV) infection E-9. Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection.
E-10. History or evidence of any auto-immune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
E-11. Subjects with another pathology requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
E-12. Known hypersensitivity to any component of the products (study drug or ingredients) E-13. Concurrent administration of any other antitumor therapy E-14. Clinically significant, uncontrolled heart disease (including history of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality within 12 months of screening).
E-15. Vaccinated with live attenuated vaccines within 4 weeks of the first dose of the study drug E-16. Pregnant or breast-feeding female patient E-17. Patient under guardianship or deprived of his liberty by a judicial or administrative decision, patients under safeguards of justice or incapable of giving its consent, patients undergoing psychiatric care under duress E-18. Participation in another clinical study with an investigational product during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Population: relapsed/refractory ALK+ ALCL with progressive disease after treatment (including chemotherapy and ALK inhibitor and/or brentuximab vedotin).
|
Induction: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) iv Q2W until CR Evaluation of response as defined below, including biopsy in case of residual masses at Week 24 Maintenance: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) Q4W Total duration of treatment (induction + maintenance) = 24 months
Other Names:
|
Experimental: Cohort 2
Population: patients with a relapsed/refractory ALCL, having achieved CR with a treatment including ALK-inhibitor or Brentuximab vedotin of at least 2 months and for whom HSCT is considered for their consolidation therapy.
In this case, nivolumab would be considered as consolidative immunotherapy instead as HSCT.
|
Induction: nivolumab 3 mg/kg iv Q2W for 4 doses (Wk0, Wk2, Wk4 and Wk6) Maintenance: nivolumab 3 mg/kg Q4W, for 25 doses, starting at Week 8 (14 days after the last induction dose) Total duration of treatment (induction + maintenance) = 24 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cohort 1 - Best objective response rate (Complete Response + Partial Response)
Time Frame: within the first 24 weeks
|
In case of PET-positive residual masses after 24 weeks of induction treatment, a resection/biopsy must be performed by week 24.
A residual mass proven to be pathologically negative for disease after resection or limited biopsy is considered as CR after discussion with the Coordinating investigator.
|
within the first 24 weeks
|
Cohort 2 - Progression Free Survival
Time Frame: up to 12 months
|
PFS is defined as the time since the inclusion in the trial to the first event among relapse and death (whatever the cause of death).
|
up to 12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Véronique Minard, Pr, Gustave Roussy, Cancer Campus, Grand Paris
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Disease Attributes
- Lymphoma, T-Cell
- Lymphoma
- Disease Progression
- Lymphoma, Large-Cell, Anaplastic
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
Other Study ID Numbers
- 2018-001447-31
- 2018/2706 (Other Identifier: CSET number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma
-
BeiGeneCompletedCutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditionsChina, Taiwan, Germany, France, Canada, Italy
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...Not yet recruitingHodgkin Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Anaplastic Large Cell Lymphoma, ALK-negative | CD30-Positive Diffuse Large B-Cell Lymphoma | Anaplastic Large Cell Lymphoma, T Cell and Null Cell TypeUnited States
-
Fox Chase Cancer CenterWithdrawnAnaplastic Large Cell Lymphoma, ALK-PositiveUnited States
-
University of WashingtonNational Cancer Institute (NCI)WithdrawnAnaplastic Large Cell Lymphoma, ALK-Positive | CD30-Positive Neoplastic Cells Present | Systemic Anaplastic Large Cell LymphomaUnited States
-
University of Milano BicoccaPfizerRecruitingAnaplastic Large Cell Lymphoma, ALK-PositiveItaly
-
University Hospital, ToulouseInstitut National de la Santé Et de la Recherche Médicale, FranceActive, not recruitingALK-Positive Anaplastic Large Cell LymphomaFrance
-
University of Milano BicoccaCompletedAnaplastic Large Cell Lymphoma, ALK-PositiveItaly
-
Mingzhi ZhangUnknownALK-Positive Anaplastic Large Cell LymphomaChina
-
The Lymphoma Academic Research OrganisationPfizer; Takeda; Hôpital Necker-Enfants Malades; Fondation ARCCompletedAnaplastic Large Cell Lymphoma, ALK-PositiveFrance
-
Arbeitsgemeinschaft medikamentoese TumortherapieTerminatedALK+ Anaplastic Large Cell LymphomaAustria
Clinical Trials on Nivolumab cohort 1
-
Janssen Research & Development, LLCCompletedRelapsed or Refractory Hodgkin LymphomaFrance, Germany
-
AstraZenecaActive, not recruitingCOVID-19, SARS-CoV-2Japan
-
XOMA (US) LLCCompletedCongenital HyperinsulinismUnited Kingdom, United States
-
Janssen Research & Development, LLCPharmacyclics LLC.CompletedCD20-positive B-cell Non-Hodgkin LymphomaUnited States, France
-
Masonic Cancer Center, University of MinnesotaCompleted
-
PfizerCompleted
-
Akesobio Australia Pty LtdCompletedAtopic DermatitisNew Zealand, Australia
-
Anthos Therapeutics, Inc.CovanceCompletedAtrial FibrillationUnited States
-
International Maternal Pediatric Adolescent AIDS...National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsRecruitingHIV InfectionUnited States, Botswana, Brazil, Haiti, Tanzania, Thailand, Kenya, South Africa, Malawi, Uganda, Zimbabwe